spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  AT2220 

 HSMN NewsFeed - 20 Aug 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2013
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 8 Jan 2009
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2007
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Mar 2007
Amicus Therapeutics Announces Return of John F. Crowley as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2007
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
Amicus Therapeutics Appoints Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Sep 2006
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 5 Jul 2006
Amicus Therapeutics Adds Glenn P. Sblendorio to Board of Directors
Biopharmaceuticals Personnel
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.